Brief Review of Cannabinoid Therapeutic Potential for Neurological Diseases Including MS, Pain, and Glaucoma | Research

The takeaway

Advances in understanding cannabinoid pharmacology and the endocannabinoid system have opened new treatment strategies for neurological and psychiatric diseases, with CB1 agonists showing potential for spasticity, pain, and inflammation, and CB1 antagonists for Parkinson's disease.

Read this if you want a quick overview of the range of neurological conditions that cannabinoid-based treatments might address.

CB1 agonists proposed for spasticity and pain; CB1 antagonists proposed for Parkinson's disease

What the researchers found

This brief review summarized how recent advances in understanding THC's pharmacological properties and the endocannabinoid system have created new therapeutic opportunities.

Potential therapeutic applications for CB1 receptor agonists include managing spasticity and tremor in MS and spinal cord injury, pain, inflammatory disorders, glaucoma, bronchial asthma, cancer, and vasodilation in advanced cirrhosis.

CB1 receptor antagonists were identified as having therapeutic potential for Parkinson's disease, based on the rationale that blocking endocannabinoid activity in the basal ganglia could improve motor function.

The review also noted the contributions of Dr. Julius Axelrod to research on the neuroprotective actions of cannabinoids.

Why it matters

This concise review highlighted the breadth of neurological conditions that might benefit from cannabinoid-based treatments, emphasizing that both activating and blocking cannabinoid receptors could have therapeutic value depending on the condition.

The numbers in context

CB1 agonist targets: spasticity, tremor, pain, inflammation, glaucoma, asthma, cancer, cirrhosis. CB1 antagonist target: Parkinson's disease.

How the study worked

Brief narrative review summarizing recent advances in cannabinoid pharmacology and therapeutic potential for neurological and psychiatric diseases. Referenced both agonist and antagonist therapeutic applications.

What this study cannot tell us

Very brief review that provides limited detail on the evidence for each therapeutic application. Many listed applications were based on preclinical rather than clinical evidence. The review format was more a summary of possibilities than a critical evaluation.

How to read the evidence

Brief narrative review listing potential therapeutic applications. Most applications discussed were supported by preclinical rather than clinical evidence.

When this study was published

Published in 2006. Clinical evidence for some of these applications (particularly MS spasticity) has grown substantially since then.

The bigger picture

The idea that CB1 antagonists might help Parkinson's disease was a novel therapeutic angle at the time. While this specific application has not been proven clinically, it illustrates the complexity of the endocannabinoid system where both too much and too little activity can be problematic in different contexts.

Questions still open

Which of these proposed therapeutic applications will prove effective in clinical trials? Can CB1 antagonists improve Parkinson's motor symptoms without the psychiatric side effects seen with rimonabant?

Common questions

What neurological diseases might cannabinoids treat?

This review listed potential applications for MS spasticity, tremor, pain, inflammatory conditions, glaucoma, and possibly Parkinson's disease (using CB1 antagonists rather than agonists). Clinical evidence has since grown strongest for MS-related symptoms.

Could cannabinoid blockers help with Parkinson's?

The review proposed CB1 receptor antagonists as having therapeutic potential for Parkinson's disease. This is a different approach from using cannabinoid agonists, and the clinical evidence remains limited.

Read the original research

Implication of cannabinoids in neurological diseases.

Cellular and molecular neurobiology, 26(4-6), 579-91

View on PubMed ↗

Citation

Alsasua del Valle, Angela. (2006). Implication of cannabinoids in neurological diseases.. Cellular and molecular neurobiology, 26(4-6), 579-91.